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Introduction: Malignant pleural mesothelioma (MPM) is an ag-
gressive malignant tumor of mesothelial origin associated with
asbestos exposure. MPM has a limited response to conventional
chemotherapy and radiotherapy so diagnosing MPM early is very
important. Vascular endothelial growth factor (VEGF) is an auto-
crine growth factor for MPM. Here, we investigated the serum levels
of VEGF in patients with MPM in comparison with a population that
had been exposed to asbestos without developing MPM.
Methods: Serum concentrations of VEGF were measured in 51
patients with MPM and 42 individuals with benign asbestos-related
diseases (asbestosis or pleural plaques) or who were healthy despite
asbestos exposure.
Results:We demonstrated that patients with MPM had significantly
higher serum levels of VEGF than a population who had been
exposed to asbestos but had not developed MPM, and the patients
with advanced stage MPM showed higher levels of VEGF than the
early stage patients with MPM. The difference in overall survival
between the groups with VEGF serum levels lower and higher than
the assumed cutoff of 460 pg/ml was significant.
Conclusions: Our data suggest that the VEGF serum concentration
could be a useful marker for screening MPM among asbestos-
exposed individuals and as a prognostic factor.
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Malignant pleural mesothelioma (MPM) is an aggressivemalignant tumor of mesothelial origin associated with
asbestos exposure.1–3 Although recently, asbestos usage has
decreased throughout the world, the incidence of MPM is
expected to markedly increase over the next few decades
because there is the long latency period (20–40 years) be-
tween asbestos exposure and tumor development.4 MPM
shows limited response to conventional chemotherapy and
radiotherapy. Although recently, the multitargeted antifolate
pemetrexed has been approved as a first-line agent in com-
bination with cisplatin for the treatment of MPM, overall
survival remains very poor5 with a median survival duration
of 8 to 18 months.6 In several centers, potentially curative
surgery combined with some form of adjuvant therapy has
been performed. Such early therapeutic intervention seems to
be beneficial than late intervention. So, diagnosing MPM at
an early stage is very important.1 However, diagnosis can
often be very difficult in histologic studies. In the diagnosis of
lung cancer, serum markers such as CEA, CYFRA, proGRP,
and SCC provide supportive roles to confirm the diagnosis.
Serum biomarkers for MPM such as mesothelin and os-
teopontin7,8 have been reported and used to assist the diag-
nosis of MPM. For the further improvement of specificity and
sensitivity of diagnosis, research into the development of
novel biologic markers is urgently required.
Tumor growth and metastasis are associated with an-
giogenesis. We previously reported that vascular endothelial
growth factor (VEGF), a potent mitogen for the vascular
endothelium, is associated with bleomycin-induced pulmo-
nary fibrosis in mice.9 MPM is a malignant transformation of
mesothelial cells, which originate from mesenchymal cells
similar to lung fibroblasts. In this study, we evaluated the
clinical role of VEGF in MPM and found that patients with
MPM had significantly higher serum levels of VEGF than a
population with a history of asbestos exposure, which sug-
gested its usefulness as a marker for the screening of MPM.
Our results are consistent with previous reports demonstrat-
ing that VEGF is expressed in MPM, and moreover, that it
acts as an autocrine growth factor for MPM.10
MATERIALS AND METHODS
Patients and Serum Samples
We studied the VEGF levels in the sera collected from
93 individuals presenting at the Department of Respiratory
Medicine of Hyogo College of Medicine Hospital from 2000
to 2007. All of the individuals had a documented asbestos
exposure history. Fifty-one individuals had MPM, which was
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diagnosed using histopathological samples by pathologists
skilled in the diagnosis of MPM. All patients were classified
by the staging system of the International Mesothelioma
Interest Group.11 Forty-two individuals had benign asbestos-
related diseases (asbestosis or pleural plaques) or were
healthy despite their asbestos exposure. The study was ap-
proved by our ethics committee in accordance with the 1975
Declaration of Helsinki. Informed consent was obtained from
all patients. Serum samples were collected before treatment,
immediately frozen in liquid nitrogen, and stored at 80
degrees until use.
Measurement of VEGF
The serum VEGF concentrations were measured using
an enzyme-linked immunosorbent assay Kit (R&D Systems,
Oxford, United Kingdom) according to the manufacturers’
instructions.
Statistical Analysis
The nonparametric Mann-Whitney U test was used to
compare two groups of serum samples. Comparisons of data
between various groups of serum samples were performed
with the nonparametric Kruskal-Wallis test followed by the
Mann-Whitney U test. In all tests, a p value less than 0.05 was
considered significant. To estimate the significance of serum
VEGF values, receiver operating characteristic (ROC)
curves, areas under the ROC curves, and their 95% confi-
dence intervals were calculated using standard techniques. To
examine the cutoff values for serum levels, we calculated the
total sensitivity and specificity for each cutoff value and then
chose the cutoff values that maximized each factor. Estimates
of the probability of survival were calculated by the Kaplan-
Meier method and compared using the log-rank test. To
evaluate the VEGF prognostic significance on survival of
patients with MPM, Cox’s proportional hazards regression
analysis was carried out as multivariate analysis.
RESULTS
Serum Levels of VEGF in Patients with MPM,
Those with Benign Asbestos-Related Diseases
(Asbestosis or Pleural Plaques), and Healthy
Individuals with a History of Asbestos Exposure
We recruited a total of 93 subjects with a history of
asbestos exposure. Of them, 51 had confirmed MPM, 29 had
pleural plaque and/or asbestosis, and 13 had no asbestos-
related lesions, despite their exposure to asbestos; i.e. were
healthy. Their characteristics are shown in Table 1.
The ROC curves for serum VEGF levels showed that
patients with MPM had an areas under the ROC curves, of
0.8623 in comparison to those with benign asbestos-related
diseases (asbestosis or pleural plaques) and those who were
healthy despite asbestos exposure (95% confidence interval,
0.8001–0.9245). At the optimal cutoff value of 460 pg/ml,
the diagnostic sensitivity was 70.6%, and the specificity was
88.1% (Figure 1). The serum VEGF concentration in the
patients with MPM was significantly higher (965.1  769.2
pg/ml) than that in the patients with benign asbestos-related
diseases (asbestosis or pleural plaques) and those who were
healthy (242.3  155.5 pg/ml) (p  0.0001, Figure 2A).
Moreover, scatter plots of the serum VEGF levels in the
patients with MPM showed statistically significant tendencies
to increase as the stage went up (stage I, 523.3  378.0
pg/ml; stage II, 409.6  463.2 pg/ml; stage III, 1128.8 
747.0 pg/ml; and stage IV, 1142.8  813.9 pg/ml) (p 
0.023, Figure 2B). The differences in serum VEGF levels
between the MPM histologic groups (epithelioid, 1070.6 
815.7 pg/ml; sarcomatoid, 579.8  279.0 pg/ml; biphasic,
960.5  824.7 pg/ml; and desmoplastic, 478.4  500.4
pg/ml) or sex (male, 974.4  732.8 pg/ml; female, 947.5 
873.8 pg/ml) were not statistically significant. There were no
significant differences in VEGF levels among the subjects
with benign asbestos-related diseases (asbestosis or pleural
plaques) and those who were healthy despite having a history
of asbestos exposure (242.3  155.5 pg/ml).
Relationship Between VEGF Levels and Overall
Survival
Among 51 patients with MPM, we were able to follow 44
patients closely up to 1300 days. To study the relationship
between serum VEGF levels and the patients’ clinical courses,
we separated the patients based on their serum VEGF levels at
the time of the first measurement. The first group included
patients with serum VEGF levels lower than 460 pg/ml, the
cutoff value that we used. In this group of 12 patients, the
mean serum VEGF value was 263 pg/ml (interquartile range,
46–436). The other group included the remaining 32 patients
with serum VEGF levels higher than 460 pg/ml, whose mean
serum VEGF value was 1307 pg/ml (interquartile range,
TABLE 1. Characteristics of the Patients with MPM and
Non-MPM Subjects with a History of Asbestos Exposure




















Plaque and asbestosis 3 (7.1)
None 13 (31.0)
a All of the individuals were exposed to asbestos.
s
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499–3440). The difference in overall survival between the
groups with lower and higher serum VEGF values than the
assumed cutoff point of 460 pg/ml was significant (p 
0.000119, Figure 3). Cox’s regression analysis was done on
44 patients with MPM for whom data on age, sex, histology,
stage, performance status, and treatments (chemotherapy or
surgery) were available. However, a statistically significant
prognostic effect was not found.
DISCUSSION
MPM is a malignant transformation caused by the
exposure of mesothelial cells to asbestos, which has a limited
response to conventional chemotherapy and radiotherapy,
and its prognosis is very poor. The lifetime risk of MPM is
associated with occupational and/or environmental asbestos
exposure history.12 Because of the long latency period (typ-
ically longer than 30 years) between first asbestos exposure
and the onset of the disease, MPM remains a universally fatal
disease of increasing incidence all over the world.1,2
Although in advanced cases, resection of the tumor
only prolongs survival by about 3 months, patients with stage
IA disease survive for 5 or more years after total resection of
the tumor.8 We have screened outpatients with a history of
asbestos exposure but no symptoms for several years to detect
MPM. Because of the difficulty of the early diagnosis of
MPM by radiologic and/or histologic examinations, efficient
and practical serum biomarkers are required to aid the screen-
ing and diagnosis of MPM. To date, there have been several
reports concerning candidates for clinically useful markers
for MPM.7,8,13,14 Indeed, serum level of mesothelin-related
protein, soluble form of mesothelin, has been reported to be
useful serum marker of MPM.7 Mesothelin is thought to have
a role in cell-adhesion, cell-to-cell recognition and signaling;
however, its biologic functions in MPM cells have not been
investigated fully.
Therefore, it is important to find biologic markers with
effects on MPM cells that are closely related to MPM
progression. MPM cells are known to exhibit increased or
dysregulated growth. Several factors, including transforming
growth factor (TGF)-1 and platelet-derived growth factor,
TGF-, and interleukin-8, have been reported to be associ-
ated with MPM cells.15–20 Moreover, tumor development is
closely related to angiogenesis. Malignant tumors require
new blood vessel formation, and it has been reported that
increased vascularity in MPM is associated with a poor
prognosis.2,21 VEGF is known to be an important regulator of
angiogenesis and has critical roles in endothelial cell prolif-
eration, vascular permeability, and angiogenesis in several
FIGURE 1. Sensitivity and specificity of serum VEGF for dis-
tinguishing patients with MPM from non-MPM subjects. An
analysis that included 51 patients with MPM and 42 non-
MPM subjects with a history of asbestos exposure revealed
an area under the curve of 0.86228 (95% confidence inter-
val, 0.8001–0.9245). At a cutoff value of 460 pg/ml, the
diagnostic sensitivity was 70.6%, and the specificity was
88.1%.
FIGURE 2. Serum VEGF levels in patients with MPM and
non-MPM subjects. (A) Serum VEGF levels in non-MPM sub-
jects versus those in patients with MPM were measured as
described in Materials and Methods. (B) Serum VEGF levels
in patients with MPM divided into four stages are shown.
The nonparametric Mann-Whitney U test (A) or the nonpara-
metric Kruskal-Wallis test followed by the Mann-Whitney U
test (B) was used. The p values less than 0.05 were consid-
ered significant. The horizontal bars represent the mean
value of each group. The cutoff value is shown as a horizon-
tal line.
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inflammatory lesions.22–24 We previously reported that VEGF
is associated with bleomycin-induced pulmonary fibrosis in
mice.9 MPM is a malignant transformation of mesothelial
cells, which originate from mesenchymal cells similar to lung
fibroblasts, so it would not be surprising if VEGF was found
to be associated with MPM progression. In this study, we
evaluated the clinical role of VEGF as a serum biomarker for
screening of MPM and found that patients with MPM had
significantly higher serum levels of VEGF in comparison
with a population with a history of asbestos exposure or
healthy volunteers never exposed to asbestos (230.2  118.5
pg/ml, n 5). We also measured serum levels of VEGF from
the patients with lung cancer with pleuritis (n  10) and
found the lower VEGF levels (548.5  251.6 pg/ml, p 
0.0291) than patients with MPM, which suggested its useful-
ness as a marker for the screening of MPM.
On the other hand, paracrine and autocrine mechanisms
of several cytokines in malignant tumors have been reported.
We recently reported the autocrine and/or paracrine mecha-
nism of TGF-1 in MPM.15 VEGF has been reported to be an
autocrine growth factor of MPM.10,25 Strizzi et al.10 reported
that higher VEGF levels were found in the pleural effusion,
but not in the serum of patients with MPM than in those of
patients with nonmalignant pleural diseases. In this study, we
demonstrated higher serum VEGF levels in patients with
MPM than in patients with benign asbestos-related diseases
(asbestosis or pleural plaques) or those that were healthy
despite having a history of asbestos exposure. The discrep-
ancy between our observations and theirs with regard to
serum VEGF levels may be explained as follows: first, they
examined 12 patients with MPM and 10 patients with non-
MPM; whereas, we examined more patients and controls;
second, their patients with MPM were classified into IA (n 
1), IB (n 5), II (n 5), and III stages (n 1); whereas, our
patients included more advanced stages; and third, their
controls had acute or chronic pleural diseases, which can be
affected by inflammatory diseases. As we previously reported
in mice,9 VEGF is associated with bleomycin-induced pul-
monary fibrosis.26 On the other hand, Li et al.27 reported that
treatment with anti-VEGF neutralizing antibody suppressed
MPM progression in a mouse model, especially the formation
of pleural effusion. Although they demonstrated the preven-
tive effect of anti-VEGF neutralizing antibody on MPM
progression, mainly by preventing angiogenesis and increases
in pleural effusion rather than abrogating autocrine tumor
growth, we have some patients with advanced stage disease
that do not show pleural effusion. Because the clinical stage
of MPM is not related to the presence or absence of pleural
effusion, and the early distinction of patients with MPM
from those with benign asbestos-related diseases is neces-
sary, measuring the VEGF levels in serum seems more
useful than determining the levels in the pleural effusion in
patients with MPM.
The prognostic significance of VEGF in MPM has been
estimated.28 However, they demonstrated a significant corre-
lation between VEGF staining of resected specimens and
short survival. In this study, we demonstrated that serum
VEGF levels gradually increased according to the progres-
sion of the disease, and the Kaplan-Meier method revealed a
significant correlation between serum VEGF levels and sur-
vival, which suggested its usefulness as a marker for estimat-
ing prognosis.
In summary, we demonstrated that patients with MPM
had significantly higher serum levels of VEGF in comparison
with a population with a history of asbestos exposure that did
not develop MPM, and the patients with advanced stage
MPM showed higher levels of VEGF than patients with early
stage MPM, suggesting it as a useful serum marker for
screening for MPM in symptomless asbestosis-exposed indi-
viduals. Moreover, the Kaplan-Meier method revealed a sig-
nificant correlation between serum VEGF levels and survival,
which suggested its usefulness as a marker for estimating
prognosis.
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